Levels of red blood cell fatty acids in patients with psychosis, their unaffected siblings, and healthy controls

Schizophrenia Bulletin

Volumn 42, Issue 2, 2016, Pages 358-368

  Medema, Suzanne ^a,b   Mocking, Roel J T ^b   Koeter, Maarten W J ^b   Vaz, Frédéric M ^b   Meijer, Carin ^a,b   Haan, Lieuwe ^b   De Van Beveren, Nico J M ^a   Kahn, René ^c   De Haan, Lieuwe ^b   Van Os, Jim ^d   Wiersma, Durk ^e   Bruggeman, Richard ^e   Cahn, Wiepke ^c   Myin Germeys, Inez ^d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

AA (arachidonic acid); Endophenotype; FA (fatty acid); Familial; NA (nervonic acid); Schizophrenia

Indexed keywords

ARACHIDONIC ACID; ATYPICAL ANTIPSYCHOTIC AGENT; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; FATTY ACID; ICOSAPENTAENOIC ACID; LINOLEIC ACID; NERVONIC ACID; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG; MONOUNSATURATED FATTY ACID; UNSATURATED FATTY ACID;

ADULT; AGED; ARTICLE; CELL LEVEL; CONTROLLED STUDY; DIET; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ABUSE; DRUG USE; ERYTHROCYTE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PHENOTYPE; PRIORITY JOURNAL; PSYCHOSIS; SIBLING; METABOLISM; NORMAL HUMAN; SCHIZOPHRENIA; YOUNG ADULT;

ADULT; ARACHIDONIC ACID; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; ERYTHROCYTES; FATTY ACIDS, MONOUNSATURATED; FATTY ACIDS, UNSATURATED; FEMALE; HEALTHY VOLUNTEERS; HUMANS; LINOLEIC ACID; MALE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SIBLINGS; YOUNG ADULT;

EID: 84964885478     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbv133     Document Type: Article

References (63)

1. Insel TR. Rethinking schizophrenia. Nature. 2010;468:187-193.
2. Bartzokis G. Schizophrenia: breakdown in the well-regulated lifelong process of brain development and maturation. Neuropsychopharmacology. 2002;27:672-683.
3. Guest J, Garg M, Bilgin A, Grant R. Relationship between central and peripheral fatty acids in humans. Lipids Health Dis. 2013;12:79.
4. Das UN. Polyunsaturated fatty acids and their metabolites in the pathobiology of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013;42:122-134.
5. Assies J, Mocking RJ, Lok A, Ruhé HG, Pouwer F, Schene AH. Effects of oxidative stress on fatty acid- And one-carbonmetabolism in psychiatric and cardiovascular disease comorbidity. Acta Psychiatr Scand. 2014;130:163-180.
6. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. Molecular Biology of the Cell: Garland Science; 3rd edition. New York and London: Garland Publishing; 1994.
7. Horrobin DF, Glen AI, Vaddadi K. The membrane hypothesis of schizophrenia. Schizophr Res. 1994;13:195-207.
8. van der Kemp, WJ, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE. A meta- Analysis of the polyunsaturated fatty acid composition of erythrocyte membranes in schizophrenia. Schizophr Res. 2012;141:153-161.
9. Hoen WP, Lijmer JG, Duran M, Wanders RJ, van Beveren, NJ, de Haan, L. Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: A meta- Analysis. Psychiatry Res. 2013;207:1-12.
10. Assies J, Lieverse R, Vreken P, Wanders RJ, Dingemans PM, Linszen DH. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biol Psychiatry. 2001;49:510-522.
11. Peet M. Nutrition and schizophrenia: beyond omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2004;70:417-422.
12. Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res. 2003;62:195-204.
13. McNamara RK, Rider T, Jandacek R, Tso P. Abnormal fatty acid pattern in the superior temporal gyrus distinguishes bipolar disorder from major depression and schizophrenia and resembles multiple sclerosis. Psychiatry Res. 2014;215:560-567.
14. Evans DR, Parikh VV, Khan MM, Coussons C, Buckley PF, Mahadik SP. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot Essent Fatty Acids. 2003;69:393-399.
15. Obi FO, Nwanze EA. Fatty acid profiles in mental disease. Part 1. Linolenate variations in schizophrenia. J Neurol Sci. 1979;43:447-454.
16. Vaddadi KS, Gilleard CJ, Soosai E, Polonowita AK, Gibson RA, Burrows GD. Schizophrenia, tardive dyskinesia and essential fatty acids. Schizophr Res. 1996;20:287-294.
17. Peet M, Laugharne JD, Mellor J, Ramchand CN. Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandins Leukot Essent Fatty Acids. 1996;55:71-75.
18. Andreasen NC, Flaum M, Arndt S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry. 1992;49:615-623.
19. Korver N, Quee PJ, Boos HB, Simons CJ, de Haan, L; GROUP investigators. Genetic Risk and Outcome of Psychosis (GROUP), a multi-site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. Int J Methods Psychiatr Res. 2012;21:205-221.
20. Mocking RJ, Assies J, Lok A, et al. Statistical methodological issues in handling of fatty acid data: percentage or concentration, imputation and indices. Lipids. 2012;47:541-547.
21. Sethom MM, Fares S, Bouaziz N, et al. Polyunsaturated fatty acids deficits are associated with psychotic state and negative symptoms in patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 2010;83:131-136.
22. Bentsen H, Osnes K, Refsum H, Solberg D, Bohmer T. A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia. Transl Psychiatry. 2013;3:1-9.
23. Bentsen H, Solberg DK, Refsum H, Bøhmer T. Clinical and biochemical validation of two endophenotypes of schizophrenia defined by levels of polyunsaturated fatty acids in red blood cells. Prostaglandins Leukot Essent Fatty Acids. 2012;87:35-41.
24. Peet M, Laugharne J, Rangarajan N, Horrobin D, Reynolds G. Depleted red cell membrane essential fatty acids in drug- Treated schizophrenic patients. J Psychiatr Res. 1995;29:227-232.
25. Peet M, Shah S, Selvam K, Ramchand CN. Polyunsaturated fatty acid levels in red cell membranes of unmedicated schizophrenic patients. World J Biol Psychiatry. 2004;5:92-99.
26. Ranjekar PK, Hinge A, Hegde MV, et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 2003;121:109-122.
27. Glen AI, Glen EM, Horrobin DF, et al. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr Res. 1994;12:53-61.
28. Reddy RD, Keshavan MS, Yao JK. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr Bull. 2004;30:901-911.
29. Kemperman RF, Veurink M, van der Wal, T, et al. Low essential fatty acid and B-vitamin status in a subgroup of patients with schizophrenia and its response to dietary supplementation. Prostaglandins Leukot Essent Fatty Acids. 2006;74:75-85.
30. Haroutunian V, Katsel P, Roussos P, Davis KL, Altshuler LL, Bartzokis G. Myelination, oligodendrocytes, and serious mental illness. Glia. 2014;62:1856-1877.
31. Hashimoto M, Maekawa M, Katakura M, Hamazaki K, Matsuoka Y. Possibility of polyunsaturated fatty acids for the prevention and treatment of neuropsychiatric illnesses. J Pharmacol Sci. 2014;124:294-300.
32. Janssen CI, Kiliaan AJ. Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: The influence of LCPUFA on neural development, aging, and neurodegeneration. Prog Lipid Res. 2014;53:1-17.
33. Schwarz E, van Beveren, NJ, Ramsey J, et al. Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways. Schizophr Bull. 2014;40:787-795.
34. Peet M. The metabolic syndrome, omega-3 fatty acids and inflammatory processes in relation to schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 2006;75:323-327.
35. Rao JS, Kim HW, Harry GJ, Rapoport SI, Reese EA. Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients. Schizophr Res. 2013;147:24-31.
36. Sommer IE, van Westrhenen, R, Begemann MJ, de Witte, LD, Leucht S, Kahn RS. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: An update. Schizophr Bull. 2014;40:181-191.
37. Hibbeln JR, Makino KK, Martin CE, Dickerson F, Boronow J, Fenton WS. Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder. Biol Psychiatry. 2003;53:431-441.
38. Drexhage RC, Weigelt K, van Beveren, N, et al. Immune and neuroimmune alterations in mood disorders and schizophrenia. Int Rev Neurobiol. 2011;101:169-201.
39. Bentsen H, Solberg DK, Refsum H, et al. Bimodal distribution of polyunsaturated fatty acids in schizophrenia suggests two endophenotypes of the disorder. Biol Psychiatry. 2011;70:97-105.
40. Bartzokis G. Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments. Neuropharmacology. 2012;62:2137-2153.
41. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res. 2002;58:1-10.
42. Yao Jk, Stanley JA, Reddy RD, Keshavan MS, Pettegrew JW. Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites. Biol Psychiatry. 2002;52:823-830.
43. Yao JK, van Kammen, DP, Welker JA. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr Res. 1994;13:217-226.
44. Zhang XY, Tan YL, Cao LY, et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res. 2006;81:291-300.
45. Bartzokis G, Lu PH, Stewart SB, et al. In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia. Schizophr Res. 2009;113:322-331.
46. Bartzokis G, Lu PH, Amar CP, et al. Long acting injection versus oral risperidone in first-episode schizophrenia: Differential impact on white matter myelination trajectory. Schizophr Res. 2011;132:35-41.
47. Gilca M, Piriu G, Gaman L, Delia C, Iosif L, Atanasiu V, Stoian I. A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics. Psychopharmacology. 2014;231:4703-4710.
48. Thompson PM, Bartzokis G, Hayashi KM, et al; HGDH Study Group. Time-lapse mapping of cortical changes in schizophrenia with different treatments. Cereb Cortex. 2009;19:1107-1123.
49. Mahadik SP, Evans D, Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25:463-493.
50. Amminger GP, Schäfer MR, Papageorgiou K, et al. Longchain omega-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67:146-154.
51. Emsley R, Chiliza B, Asmal L, et al. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in firstepisode schizophrenia. Schizophr Res. 2014;158:230-235.
52. Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry. 2000;47:8-21.
53. Mossaheb N, Schäfer MR, Schlögelhofer M, et al. Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: When do they begin to be effective? Schizophr Res. 2013;148:163-167.
54. Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T. Early interventions to prevent psychosis: systematic review and meta- Analysis. BMJ. 2013;346:f185.
55. Strassnig M, Singh Brar J, Ganguli R. Dietary fatty acid and antioxidant intake in community-dwelling patients suffering from schizophrenia. Schizophr Res. 2005;76:343-351.
56. Irving CB, Mumby-Croft R, Joy LA. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev. 2006; 3:1-38.
57. Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. Prog Lipid Res. 2008;47:348-380.
58. Harris WS, Varvel SA, Pottala JV, Warnick GR, McConnell JP. Comparative effects of an acute dose of fish oil on omega-3 fatty acid levels in red blood cells versus plasma: implications for clinical utility. J Clin Lipidol. 2013;7:433-440.
59. Skosnik PD, Yao JK. From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia? Prostaglandins Leukot Essent Fatty Acids. 2003;69:367-384.
60. Drexhage RC, van der Heul-Nieuwenhuijsen, L, Padmos RC, et al. Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients. Int J Neuropsychopharmacol. 2010;13:1369-1381.
61. Van Beveren, NJ, Schwarz E, Noll R, et al. Evidence for disturbed insulin and growth hormone signaling as potential risk factors in the development of schizophrenia. Transl Psychiatry. 2014;4:e430.
62. Schwarz E, Guest PC, Rahmoune H, et al. Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2012;17:494-502.
63. Peters BD, Machielsen MW, Hoen WP, et al. Polyunsaturated fatty acid concentration predicts myelin integrity in earlyphase psychosis. Schizophr Bull. 2013;39:830-838.